Abstract
In experiments on rats with cerebral ischemia (30-min occlusion of carotid arteries), the novel calcium antagonist Cerebrocrast (0.4 microgram.kg-1.min-1 i.v. for 15 min) was found to provide the functional maintenance of the parietal cerebral bed in the postischemic period by improving cerebral hemodynamics, reducing the number of highly narrowed capillaries. The agent prevented the erythrocytic accumulation of lipid peroxidation (LPO) products (diene conjugates and Schiff bases) in the intra- and postischemic periods, promoted the maintenance of viscoelastic properties during LPO activation.
Publication types
-
Comparative Study
-
English Abstract
MeSH terms
-
Acute Disease
-
Animals
-
Calcium Channel Blockers / pharmacology*
-
Calcium Channel Blockers / therapeutic use
-
Cerebrovascular Circulation / drug effects*
-
Cerebrovascular Circulation / physiology
-
Dihydropyridines / pharmacology*
-
Dihydropyridines / therapeutic use
-
Drug Evaluation, Preclinical
-
Ischemic Attack, Transient / metabolism
-
Ischemic Attack, Transient / physiopathology
-
Ischemic Attack, Transient / prevention & control*
-
Lipid Peroxidation / drug effects
-
Male
-
Microcirculation / drug effects
-
Microcirculation / physiology
-
Rats
-
Vasodilator Agents / pharmacology*
-
Vasodilator Agents / therapeutic use
Substances
-
Calcium Channel Blockers
-
Dihydropyridines
-
Vasodilator Agents
-
2,6-dimethyl-3,5-bis(2'-propoxyethoxycarbonyl)-4-(2''-difluoromethoxyphenyl)-1,4-dihydropyridine